Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals, Inc.（SNDX）股东结构
基于 13F 申报与流通股数据，展示机构、内部人与公众持股结构；下方为前十大机构、机构动向与内部人交易。
SEC 13F · FMP · SNDX · 截至 2025年9月30日
股东结构概览
247
机构持有人数
▲ 12 vs Q2
$1.56B
机构持仓总市值
▲ $604.79M vs Q2
88.61M
总流通股
freeFloat 89.80%
101.31M
13F 申报持股数
▼ 447,533 vs Q2
机构持仓% = 13F 持股数 ÷ 总流通股。内部人% = 100 − 自由流通率。散户% = 自由流通率 − 机构%。数据来源：FMP /symbol-positions-summary + /shares-float + SEC EDGAR。
前10大机构持仓
SNDX 最大股东 · 机构持仓
Q3 2025 · SEC 13F
显示前 10 家
| 机构 | 持股数 | 占比 | 权重 | 市值 | 申报日 | 变动 |
|---|---|---|---|---|---|---|
BLACKROCK, INC. pharmaceutical preparations | 8.63M | 9.99% | 9.99% | $132.70B | Nov 12, 2025 | ▼ 1.83M |
KYNAM CAPITAL MANAGEMENT, LP pharmaceutical preparations | 8.52M | 9.87% | 9.87% | $131.08B | Nov 14, 2025 | — held |
GOLDMAN SACHS GROUP INC pharmaceutical preparations | 5.49M | 6.35% | 6.35% | $84.41B | Nov 14, 2025 | ▼ 310.8K |
VANGUARD GROUP INC pharmaceutical preparations | 5.14M | 5.95% | 5.95% | $79.06B | Nov 7, 2025 | ▲ 104.7K |
POINT72 ASSET MANAGEMENT, L.P. pharmaceutical preparations | 4.26M | 4.93% | 4.93% | $65.46B | Nov 14, 2025 | ▲ 2.13M |
STATE STREET CORP pharmaceutical preparations | 3.85M | 4.46% | 4.46% | $59.29B | Nov 14, 2025 | ▲ 410.8K |
BANK OF AMERICA CORP /DE/ pharmaceutical preparations | 3.70M | 4.28% | 4.28% | $56.89B | Feb 3, 2026 | ▼ 141.1K |
EVERSEPT PARTNERS, LP pharmaceutical preparations | 3.47M | 4.02% | 4.02% | $53.34B | Nov 14, 2025 | ▼ 598.0K |
ADAGE CAPITAL PARTNERS GP, L.L.C. pharmaceutical preparations | 3.31M | 3.84% | 3.84% | $50.95B | Nov 14, 2025 | ▲ 1.88M |
KINGDON CAPITAL MANAGEMENT, L.L.C. pharmaceutical preparations | 2.50M | 2.90% | 2.90% | $38.46B | Nov 14, 2025 | ▲ 400.0K |
数据来源：SEC 13F 申报文件。变动标识：isNew / isSoldOut / changeInSharesNumber。
机构仓位变动
Q3 2025 对比上季度
Q3 2025
27
增持
+11.24M 股2
新建仓
首次建仓18
减持
−7.10M 股0
清仓
完全退出净股数变化（前50家）
+4.14M
+11.24M / −7.10M
净新增持仓人
+11
新建 2 个 / 退出 0 个
基于前50家最大机构持仓统计，全市场实际数量可能不同。
内幕交易买卖情绪
SNDX 内幕交易记录
数据来源：SEC Form 4
近期内部人员以卖出为主。 卖出可能源于预定的 10b5-1 计划，不代表负面展望。
0
买入笔数
2
卖出笔数
0.00
买卖比
$0M
卖出总金额
最近内幕交易记录
最近10条 · 仅普通股
| 姓名 · 职位 | 日期 | 类型 | 股数 | 价格 | 金额 | 交易后持股 | 申报 |
|---|---|---|---|---|---|---|---|
Goldan Keith A. Chief Financial Officer | Jun 1, 2026 | Sale | 1,177 | $18.99 | $22.4K | 139.3K | Form 4 ↗ |
Metzger Michael A Chief Executive Officer | Jun 1, 2026 | Sale | 6,847 | $18.99 | $130.0K | 484.8K | Form 4 ↗ |
Metzger Michael A Chief Executive Officer | Feb 9, 2026 | Sale | 17,159 | $21.03 | $360.8K | 491.7K | Form 4 ↗ |
Goldan Keith A. Chief Financial Officer | Feb 9, 2026 | Sale | 3,410 | $21.03 | $71.7K | 140.4K | Form 4 ↗ |
Metzger Michael A Chief Executive Officer | Feb 4, 2026 | Award | 144,600 | — | — | 516.3K | Form 4 ↗ |
Metzger Michael A Chief Executive Officer | Feb 6, 2026 | Sale | 7,412 | $20.62 | $152.8K | 508.8K | Form 4 ↗ |
Metzger Michael A Chief Executive Officer | Feb 4, 2026 | Award | 440,000 | $20.43 | $8.99M | 440.0K | Form 4 ↗ |
Metzger Michael A Chief Executive Officer | Feb 4, 2026 | Award | 73,000 | — | — | 371.7K | Form 4 ↗ |
Goldan Keith A. Chief Financial Officer | Feb 4, 2026 | Award | 30,750 | — | — | 145.9K | Form 4 ↗ |
Goldan Keith A. Chief Financial Officer | Feb 6, 2026 | Sale | 2,082 | $20.62 | $42.9K | 143.8K | Form 4 ↗ |
数据来源：SEC Form 4。买卖方向：acquisitionOrDisposition A=买入，D=卖出。已排除 RSU 归属（M-Exempt）。
关于机构与内部人持股结构
Syndax Pharmaceuticals, Inc.（SNDX）主要由机构投资者持有，机构持股比例约为 100.0%。公司内部人员持股约 10.20%，散户及公众持股约占剩余的 0.00%。
Syndax Pharmaceuticals, Inc. 最大机构股东为 BLACKROCK, INC.，截至 September 30, 2025 持有约 8.63 million 股，占总流通股的 9.99%。
目前共有 247 家机构持有 SNDX 股票，合计持仓市值约 $1.56 billion，数据来源为最新 SEC 13F 申报。
常见问题
SNDX ownershipSyndax Pharmaceuticals, Inc.（SNDX）主要由机构投资者持有，机构持股约 100.0%。最大股东为 BLACKROCK, INC.，持股比例 9.99%。内部人员持股约 10.20%。数据来源 SEC Form 13F，截至 September 30, 2025。